Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Operating Leases: 2023-2025

Historic Operating Leases for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Sep 2025 value amounting to $8.4 million.

  • Centessa Pharmaceuticals' Operating Leases fell 6.40% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 million, marking a year-over-year decrease of 6.40%. This contributed to the annual value of $8.3 million for FY2024, which is 6.77% down from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Operating Leases stood at $8.4 million for Q3 2025, which was down 1.78% from $8.6 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Operating Leases ranged from a high of $9.7 million in Q1 2023 and a low of $8.3 million during Q4 2024.
  • Moreover, its 3-year median value for Operating Leases was $9.0 million (2024), whereas its average is $9.0 million.
  • Data for Centessa Pharmaceuticals' Operating Leases shows a maximum YoY declined of 6.77% (in 2024) over the last 5 years.
  • Over the past 3 years, Centessa Pharmaceuticals' Operating Leases (Quarterly) stood at $8.9 million in 2023, then declined by 6.77% to $8.3 million in 2024, then fell by 6.40% to $8.4 million in 2025.
  • Its Operating Leases stands at $8.4 million for Q3 2025, versus $8.6 million for Q2 2025 and $8.7 million for Q1 2025.